Pfizer Forecasts Flat 2026 Sales and Lower Profit as COVID Demand Falls; PFE Dividend Remains $0.43
Pfizer’s latest outlook is setting the tone for how investors may view the drugmaker’s post-pandemic transition in 2026: steady underlying growth ambitions, but a near-term financial “air pocket” as COVID-19 revenue continues to shrink and several products face patent and